Category: 3. Business

  • Assessing TKO Group Holdings After a 63.6% Surge and New Media Rights Deals

    Assessing TKO Group Holdings After a 63.6% Surge and New Media Rights Deals

    If you’re holding TKO Group Holdings stock or considering it for your portfolio, you may be facing a classic investor’s dilemma: whether to hold, buy more, or think about taking some chips off the table after that impressive run. Over the past year, TKO Group Holdings has risen by 63.6%, which is a notably strong performance compared to most stocks. Even after accounting for a recent 6.1% drop over the past month, the stock remains up 30.9% year-to-date. This signals plenty of interest and perhaps some changing perceptions about its future prospects.

    What has driven these movements? Recent headlines have focused on the group’s ongoing integration of major sports and entertainment properties, along with strategic partnerships that have caught investor attention. Some of the momentum earlier in the year can be traced to enthusiasm around new media rights deals and expansion into international markets, highlighting TKO’s global ambitions. Not every news cycle has been a net positive, though. Recent concerns about regulatory uncertainties and higher-than-average volatility appear to have tempered sentiment and may explain the latest dip.

    With all that activity in mind, let’s look at the numbers. Using the valuation score, a straightforward method that adds one point for each of six checks passed, TKO Group Holdings currently scores 0 out of 6. At first glance, that result may seem concerning, but the story is rarely so straightforward. Next, we’ll examine how different valuation approaches compare to TKO’s current price and explore a smarter way to understand what the market may be overlooking.

    TKO Group Holdings scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Discounted Cash Flow (DCF) model is a popular valuation method that forecasts a company’s future cash flows and discounts them back to today’s value in dollars. By doing this, investors can estimate what a business is intrinsically worth right now, based on its ability to generate cash in the future.

    For TKO Group Holdings, the latest reported Free Cash Flow stands at $721.8 million. Analyst estimates project robust growth in the coming years, with free cash flow expected to reach $1.99 billion by 2029. Estimates for the next five years are based on analyst predictions, while projections beyond that use extrapolation. This methodology combines analysts’ near-term insights with longer-term industry assumptions to provide a balanced outlook.

    Continue Reading

  • What Etsy (ETSY)’s Launch of AI Seller Hub Means for Shareholders

    What Etsy (ETSY)’s Launch of AI Seller Hub Means for Shareholders

    • Etsy has recently introduced a Seller Community Hub featuring AI-powered search tools and enhanced resources to support active sellers during the busy holiday shopping season.

    • This new platform aims to deepen marketplace engagement and streamline seller experiences, potentially reinforcing Etsy’s competitive position among global e-commerce players.

    • We’ll explore how the launch of the AI-powered Seller Community Hub could inform Etsy’s broader investment narrative and platform growth outlook.

    We’ve found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

    To be a shareholder in Etsy, you need to believe that the company can reignite Gross Merchandise Sales growth and revitalize buyer engagement, both of which are under pressure from several quarters of decline. The recent launch of the AI-powered Seller Community Hub supports marketplace innovation and seller retention for the holiday season, but does not meaningfully change the near-term catalyst, the upcoming earnings report, with market focus on margin trends and active buyer numbers, nor does it mitigate the primary risk of ongoing GMS and buyer attrition.

    Among Etsy’s latest moves, the appointment of Rafe Colburn as Chief Product and Technology Officer comes at a pivotal point. This leadership change is especially relevant given heightened execution risks tied to AI, app adoption, and loyalty initiatives, which are central to management’s efforts to stabilize performance and restore buyers to the platform.

    But as Shopify, Amazon, and others intensify the fight for digital marketplace dominance, investors should keep in mind the continuing impact of…

    Read the full narrative on Etsy (it’s free!)

    Etsy’s outlook suggests revenues of $3.2 billion and earnings of $377.3 million by 2028. This is based on annual revenue growth of 3.5% and an earnings increase of $213.3 million from the current $164.0 million.

    Uncover how Etsy’s forecasts yield a $66.27 fair value, a 10% downside to its current price.

    ETSY Community Fair Values as at Oct 2025

    Six investors in the Simply Wall St Community placed Etsy’s fair value between US$66 and US$122 per share, showing a spread of nearly US$56 in expectations. Against this backdrop, many are weighing the company’s AI-powered personalization push as a potential engine for future conversion and revenue gains, see all sides of the case for yourself.

    Explore 6 other fair value estimates on Etsy – why the stock might be worth 10% less than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ETSY.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • A Look at IAMGOLD (TSX:IMG) Valuation Following Recent Share Price Pullback

    A Look at IAMGOLD (TSX:IMG) Valuation Following Recent Share Price Pullback

    IAMGOLD (TSX:IMG) shares have been active lately, attracting attention from investors interested in commodity stocks. The company’s recent moves and performance are prompting a closer look at valuation and growth prospects this year.

    See our latest analysis for IAMGOLD.

    IAMGOLD’s share price has pulled back 11.4% over the past week after a sprinting 74.9% climb in the last three months. This reflects both shifting sector sentiment and the company’s impressive year-to-date gain of 107%. Over the longer term, its 3-year total shareholder return stands out at more than 750%, signaling that momentum is still strong even with the latest short-term dip.

    If sharp moves in gold stocks have your attention, it’s a good moment to broaden your scope and discover fast growing stocks with high insider ownership

    Given such rapid gains, the crucial question becomes whether IAMGOLD’s impressive rally still leaves room for upside, or if the market has already factored in all of the company’s growth potential. Is this a buying opportunity, or is everything priced in?

    IAMGOLD’s most widely followed narrative estimates fair value at $20.43, significantly above its recent close of $16.62. This difference frames the stock as having further upside, with analyst projections at the core of the narrative’s reasoning.

    The successful ramp-up and ahead-of-schedule capacity achievement at the Côté Gold mine, coupled with consistent production and ongoing cost optimization, set the stage for a material near-term increase in gold output, which should significantly boost future revenues and cash flow as temporary ramp-up costs subside.

    Read the complete narrative.

    Want to know what fuels this bullish outlook? The narrative hangs on ambitious growth targets and bold profit assumptions for the years ahead. Major forecast upgrades, margin trajectories, and a notable shift in valuation multiples are at play. Find out what sets IAMGOLD’s fair value apart from the pack.

    Result: Fair Value of $20.43 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent net debt and the heavy reliance on just a few key mines continue to threaten IAMGOLD’s future margins and long-term earnings growth.

    Find out about the key risks to this IAMGOLD narrative.

    If these views don’t quite align with your perspective, or you want to dig deeper and make sense of the numbers yourself, you can build your own case quickly and easily by using Do it your way.

    A great starting point for your IAMGOLD research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

    Smart investors broaden their horizons. Don’t miss your chance to uncover potential winners by using these powerful tools to find standout opportunities beyond IAMGOLD.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include IMG.TO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • ASX Growth Companies With High Insider Ownership For October 2025

    ASX Growth Companies With High Insider Ownership For October 2025

    As the Australian market shows signs of a modest upswing, buoyed by geopolitical developments and commodity price movements, investors are keenly observing potential growth opportunities. In this environment, companies with high insider ownership often attract attention as they may indicate strong confidence from those closest to the business, making them intriguing prospects for those seeking growth in the current economic climate.

    Name

    Insider Ownership

    Earnings Growth

    Wisr (ASX:WZR)

    12.6%

    89.9%

    Titomic (ASX:TTT)

    11.3%

    74.9%

    Polymetals Resources (ASX:POL)

    37.7%

    108%

    Pointerra (ASX:3DP)

    19%

    110.3%

    Newfield Resources (ASX:NWF)

    31.5%

    72.1%

    IRIS Metals (ASX:IR1)

    21.6%

    144.4%

    Findi (ASX:FND)

    33.6%

    91.2%

    Echo IQ (ASX:EIQ)

    19.1%

    49.9%

    BlinkLab (ASX:BB1)

    35.5%

    101.4%

    Adveritas (ASX:AV1)

    17.3%

    96.8%

    Click here to see the full list of 96 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

    Here’s a peek at a few of the choices from the screener.

    Simply Wall St Growth Rating: ★★★★☆☆

    Overview: Catapult Sports Ltd is a sports science and analytics company that develops and supplies technologies to enhance athlete and team performance across various regions including Australia, Europe, the Middle East, Africa, the Asia Pacific, and the Americas with a market cap of A$2.11 billion.

    Operations: The company’s revenue is derived from three main segments: Tactics & Coaching ($36.66 million), and Performance & Health ($63.47 million).

    Insider Ownership: 14.5%

    Catapult Sports, recently added to the S&P/ASX 200 Index, has completed a follow-on equity offering of A$130 million. The company is forecast to achieve earnings growth of 68.69% annually and become profitable within three years, outpacing the average market growth. While revenue growth at 15% per year is slower than desired for high-growth entities, it still surpasses the Australian market’s average rate. The company’s recent acquisition discussions and insider ownership could drive strategic advantages.

    ASX:CAT Earnings and Revenue Growth as at Oct 2025

    Simply Wall St Growth Rating: ★★★★☆☆

    Overview: Mineral Resources Limited, with a market cap of A$8.84 billion, offers mining services across Australia, Asia, and internationally through its subsidiaries.

    Operations: The company’s revenue segments include A$601 million from Lithium, A$2.33 billion from Iron Ore, and A$3.30 billion from Mining Services.

    Insider Ownership: 11.4%

    Mineral Resources is poised for significant earnings growth, with profits expected to rise 63.57% annually, surpassing the Australian market’s average. Despite a challenging financial year with a A$904 million loss and substantial debt of A$5.3 billion, no major insider selling occurred recently. The company plans asset sales to improve its balance sheet while new board appointments aim to bolster governance expertise. Trading at favorable valuations compared to peers enhances its investment appeal amidst these strategic changes.

    ASX:MIN Ownership Breakdown as at Oct 2025
    ASX:MIN Ownership Breakdown as at Oct 2025

    Simply Wall St Growth Rating: ★★★★☆☆

    Overview: Supply Network Limited supplies aftermarket parts for the commercial vehicle market in Australia and New Zealand, with a market cap of A$1.62 billion.

    Operations: The company’s revenue segment is primarily from the provision of aftermarket parts for the commercial vehicle market, generating A$349.46 million.

    Insider Ownership: 40%

    Supply Network’s recent inclusion in the S&P Global BMI Index underscores its solid market position. The company reported robust financial performance, with sales reaching A$348.83 million and net income of A$40.02 million for the year ended June 2025. Forecasted earnings growth at 14.34% annually outpaces the Australian market average, while insider ownership remains stable with no significant selling activity recently observed. The appointment of Karen Phin as a director enhances board independence and expertise in capital management strategies.

    ASX:SNL Ownership Breakdown as at Oct 2025
    ASX:SNL Ownership Breakdown as at Oct 2025

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

    Companies discussed in this article include ASX:CAT ASX:MIN and ASX:SNL.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • 3 ASX Stocks Estimated To Be Trading Up To 47.3% Below Intrinsic Value

    3 ASX Stocks Estimated To Be Trading Up To 47.3% Below Intrinsic Value

    As the Australian stock market experiences a modest upswing amid geopolitical developments and commodity fluctuations, investors are keenly observing opportunities that may arise from undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be particularly appealing, as they present potential for growth when market conditions stabilize.

    Name

    Current Price

    Fair Value (Est)

    Discount (Est)

    Vault Minerals (ASX:VAU)

    A$0.715

    A$1.17

    38.6%

    Superloop (ASX:SLC)

    A$3.20

    A$5.66

    43.5%

    Resimac Group (ASX:RMC)

    A$1.12

    A$2.17

    48.3%

    NRW Holdings (ASX:NWH)

    A$4.81

    A$9.13

    47.3%

    Liontown Resources (ASX:LTR)

    A$1.22

    A$2.12

    42.4%

    James Hardie Industries (ASX:JHX)

    A$34.13

    A$61.30

    44.3%

    Credit Clear (ASX:CCR)

    A$0.285

    A$0.47

    39.2%

    CleanSpace Holdings (ASX:CSX)

    A$0.70

    A$1.38

    49.3%

    Betmakers Technology Group (ASX:BET)

    A$0.195

    A$0.32

    38.7%

    Airtasker (ASX:ART)

    A$0.37

    A$0.71

    48.1%

    Click here to see the full list of 32 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.

    Here we highlight a subset of our preferred stocks from the screener.

    Overview: Eagers Automotive Limited owns and operates motor vehicle dealerships in Australia and New Zealand, with a market cap of A$7.97 billion.

    Operations: The company generates revenue primarily from car retailing, amounting to A$12.23 billion, with an additional contribution of A$54.69 million from property.

    Estimated Discount To Fair Value: 14.0%

    Eagers Automotive is trading at A$30.57, below its fair value estimate of A$35.54, indicating potential undervaluation based on cash flows. Despite a recent strategic partnership with Mitsubishi and a follow-on equity offering raising A$501 million, interest payments are not well covered by earnings. However, earnings are forecast to grow significantly at 21.6% annually over the next three years, surpassing the Australian market’s growth rate of 14.3%.

    ASX:APE Discounted Cash Flow as at Oct 2025

    Overview: NRW Holdings Limited offers diversified contract services to the resources and infrastructure sectors in Australia, with a market cap of A$2.21 billion.

    Operations: The company’s revenue is derived from three main segments: Mining at A$1.54 billion, MET at A$932.02 million, and Civil at A$823.72 million.

    Estimated Discount To Fair Value: 47.3%

    NRW Holdings is trading at A$4.81, significantly below its estimated fair value of A$9.13, suggesting undervaluation based on cash flows. Despite a decline in net income to A$27.67 million for FY2025 and insider selling, earnings are projected to grow substantially at 30.6% annually over the next three years, outpacing the Australian market’s growth rate of 14.3%. However, the dividend yield of 3.43% is not adequately covered by earnings.

    ASX:NWH Discounted Cash Flow as at Oct 2025
    ASX:NWH Discounted Cash Flow as at Oct 2025

    Overview: Vault Minerals Limited is involved in the exploration, mine development, operations and sale of gold and gold/copper concentrate in Australia and Canada, with a market cap of A$4.85 billion.

    Operations: The company’s revenue segments consist of Deflector (A$477.79 million), Sugar Zone (A$0.23 million), Mount Monger (A$287.58 million) and Leonora Operation (A$666.50 million).

    Estimated Discount To Fair Value: 38.6%

    Vault Minerals, currently priced at A$0.72, is trading well below its estimated fair value of A$1.17, highlighting potential undervaluation based on cash flows. The company has shown a turnaround with net income reaching A$236.98 million from a loss last year and sales jumping to A$1.43 billion from A$620 million. Earnings are forecast to grow significantly at 21% annually over the next three years, supported by a share repurchase program targeting up to 10% of issued capital.

    ASX:VAU Discounted Cash Flow as at Oct 2025
    ASX:VAU Discounted Cash Flow as at Oct 2025

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ASX:APE ASX:NWH and ASX:VAU.

    This article was originally published by Simply Wall St.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Undiscovered Gems In Australia For October 2025

    Undiscovered Gems In Australia For October 2025

    As the Australian market experiences a soft upswing, buoyed by optimistic trade talks and rising commodity prices, investors are keenly watching small-cap stocks for potential opportunities. In such an environment, undiscovered gems often possess strong fundamentals and resilience to broader market fluctuations, making them appealing candidates for growth-oriented portfolios.

    Name

    Debt To Equity

    Revenue Growth

    Earnings Growth

    Health Rating

    Fiducian Group

    NA

    10.00%

    9.57%

    ★★★★★★

    Rand Mining

    NA

    10.19%

    2.74%

    ★★★★★★

    Euroz Hartleys Group

    NA

    1.82%

    -25.32%

    ★★★★★★

    Hearts and Minds Investments

    NA

    56.27%

    59.19%

    ★★★★★★

    Spheria Emerging Companies

    NA

    -1.31%

    0.28%

    ★★★★★★

    Focus Minerals

    NA

    75.35%

    51.34%

    ★★★★★★

    Djerriwarrh Investments

    2.39%

    8.18%

    7.91%

    ★★★★★★

    Energy World

    NA

    -47.50%

    -44.86%

    ★★★★★☆

    Zimplats Holdings

    5.44%

    -9.79%

    -42.03%

    ★★★★★☆

    Australian United Investment

    1.90%

    5.23%

    4.56%

    ★★★★☆☆

    Click here to see the full list of 60 stocks from our ASX Undiscovered Gems With Strong Fundamentals screener.

    Here we highlight a subset of our preferred stocks from the screener.

    Simply Wall St Value Rating: ★★★★★☆

    Overview: Diversified United Investment Limited is a publicly owned investment manager with a market cap of A$1.15 billion.

    Operations: The company generates revenue primarily from its investment activities, amounting to A$46.71 million.

    Diversified United Investment (DUI) has shown resilience with a net income of A$37.99 million for the year ending June 2025, up from A$36.03 million the previous year, reflecting steady growth in earnings per share from A$0.166 to A$0.176. Over five years, earnings have grown at an annual rate of 5%, although recent growth of 5.4% lagged behind the broader Capital Markets industry at 19.3%. The company is debt-free, contrasting with its past debt-to-equity ratio of 9%, which highlights prudent financial management despite significant insider selling recently observed over three months.

    ASX:DUI Debt to Equity as at Oct 2025

    Simply Wall St Value Rating: ★★★★☆☆

    Overview: Peet Limited is an Australian company that focuses on acquiring, developing, and marketing residential land, with a market capitalization of A$894.18 million.

    Operations: Peet generates revenue primarily through its Company Owned Projects, contributing A$313.24 million, followed by Funds Management at A$56.39 million and Joint Arrangements at A$51.88 million.

    Continue Reading

  • AI and tech are potentially the biggest equalizers Africa has ever seen, former Nvidia exec says

    AI and tech are potentially the biggest equalizers Africa has ever seen, former Nvidia exec says

    Artificial intelligence is poised to become a transformative growth driver for African economies, which will also export its own AI in the coming years, according to the head of a data infrastructure company.

    At Fortune’s Global Forum in Riyadh, Saudi Arabia, on Sunday, Amini founder and CEO Kate Kallot said her company is building computing power that will enable purpose-built AI solutions for Africa.

    The former Nvidia executive also predicted that AI will add $2.9 trillion to Africa’s economy over the next five years as governments begin to view data and computing capacity as critical infrastructure, alongside roads and hospitals. Kallot served as head of emerging areas at Nvidia before departing in 2022 to start Amini.

    As infrastructure investments grow, governments are demanding that large language models deployed in Africa actually reflect local realities, given that nearly a billion Africans are still offline while LLMs are trained on internet data, Kallot said.

    This new mindset of strategic partnerships has expanded from the governmental level to the private sector, and startups have emerged that will help shape the future of their countries and their economies, she said.

    “We’re seeing technology and AI as potentially one of the biggest equalizers that Africa has ever seen,” Kallot added.

    But that’s not yet reflected in the global narrative, which doesn’t recognize AI innovation in Africa, she pointed out.

    The reality is that the continent is actually a leader in developing AI that’s efficient, responsible, and inclusive—and the rest of the world is about to find out.

    “Within the next five to 10 years, we’re going to see African intelligence being exported in other countries across the Global South,” Kallot said.

    Changing the global narrative

    The negative narrative about Africa is costly, according to Ndidi Okonkwo Nwuneli, CEO of the global advocacy group One Campaign.

    That bias has made borrowing costs for African countries more expensive, with negative reporting about the region costing an estimated $4.2 billion. But in fact, certain sectors are seeing returns as high as 10x.

    “We’re changing the narrative, and we’re saying Africa is a return on investment, not a risk,” she told Fortune’s Diane Brady. “And this is the time to partner with us with fair financing that delivers results and delivers jobs.”

    Flipping the script is also top of mind for Boris Kodjoe, cofounder of the investment and impact platform Full Circle Africa.

    The former model and Hollywood actor noted that Africa’s diaspora—the world’s third-largest after China’s and India’s—has been structuring its capital in recent years and is key to the growth story.

    Today, Africa’s economy is young, creative, digital, and moving fast, defining itself with culture and technology rather than just its natural resources, Kodjoe explained.

    “Africa is the only region where population is getting younger, more connected, and more entrepreneurial all at the same time,” he added. “I think the world is no longer asking ‘why Africa,’ but ‘when can we get in?’ And i think the time is now.” 

    Continue Reading

  • Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

    CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts

    Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppository Applicator Demonstrates Statistically Significant Rates of Clinical Remission in Patients with UC in CESSA Phase 3 Trial

    Additional Findings Reinforce Rapid and Sustained Drug Release of ngHCA

    AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ — Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is presenting three posters highlighting pivotal new data in ulcerative colitis (UC) of the rectum research at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona. 

    “We are excited to present Cristcot’s data at ACG 2025, which showcases our meaningful contributions across the spectrum of UC research and reinforces the transformative potential of our ngHCA suppository – the first investigational agent to show rapid clinical remission in UC,” said Jennifer J. Davagian, Founder and Chief Executive Officer, Cristcot. “As we progress towards FDA submission and commercialization of our novel therapy, we are focused on close collaboration with the gastroenterology community through forums like ACG to ensure we are best positioned to address the needs of patients, providers, and payers in this field. We look forward to continuing to advance our innovative, patient-centric solutions.”

    ACG Presidential Poster Distinction Recognizes Excellence in Clinical Research

    The CESSA abstract was selected as an ACG 2025 Presidential Poster Recipient among nearly 6,000 abstracts. The distinction is reserved for approximately five percent of submissions and recognizes high-quality, novel, and clinically meaningful research contributing to advances in gastroenterology.

    Pivotal Phase 3 CESSA Trial

    Poster Title: Efficacy and Safety of a Novel Investigational Hydrocortisone Acetate Suppository Formulation and Optimized Applicator for Treatment of Active Ulcerative Colitis: Results of the Phase 3 CESSA Trial
    Key Findings: The Phase 3 CESSA trial evaluated efficacy and safety of Cristcot’s ngHCA 90 mg suppository administered with the proprietary Sephure® suppository applicator in adults with confirmed active moderate to severe UC.

    Efficacy

    • The trial achieved its primary endpoint of clinical remission at Day 29 and secondary endpoint of clinical response at Day 15, both using modified Mayo Score (MMS) criteria, demonstrating statistically significant improvements for patients treated with the ngHCA 90 mg suppository compared to those who received placebo.
      • Clinical and endoscopic remission was achieved by 21.2% (p=0.0005) of study participants in the ngHCA QD (once-daily) arm versus 1.5% of patients in the placebo arm.
      • Secondary efficacy analyses showed that treatment with ngHCA QD resulted in greater improvement in rectal bleeding and stool frequency scores at Day 15 and Day 29 versus placebo.
      • Concomitant medication for UC (stable dose) was taken by 63.5% of patients throughout the study. No non-study corticosteroids were permitted.

    Safety and Compliance

    • ngHCA was well tolerated.
    • There were no treatment-related serious adverse events (SAEs).
    • Treatment-related adverse events (TEAEs) were reported by 4.5% of patients in the QD treatment group and 7.6% in the placebo group.
    • The majority of TEAEs were mild and moderate in severity.
    • Compliance was very high – 100% of subjects in the ngHCA QD group had greater than 90% adherence with the required dosing.

    Additional details on the CESSA trial can be found in Cristcot’s January 2025 press release, available on the News page of its website.

    “There is an urgent need for a fast-acting, localized, and easy-to-administer option to manage patients with active ulcerative colitis,” said Raj Devarajan, MD, Global Medical Advisor, Cristcot, and presenting author. “I’m thrilled to share the pivotal CESSA trial results as a Presidential Poster at ACG, which marks a meaningful advancement in this area. The efficacy demonstrated in CESSA, notably clinical responses within two weeks and endoscopic remission by four weeks, has never been achieved in the moderate to severe UC population. Combined with a favorable tolerability profile, these data support this novel HCA combination product to treat UC exacerbations alongside maintenance therapies or as a monotherapy. I look forward to its continued evaluation as a new option for the many patients who continue to face gaps in effective management of this disease.”

    Innovation in Pharmacokinetics

    Title: Pharmacokinetics and Relative Bioavailability of an Investigational Hydrocortisone Acetate Suppository Administered with a Novel FDA-Cleared Applicator Versus Hydrocortisone Liquid Enema
    Key Findings: In this Phase 1 study, the ngHCA suppository administered using the Sephure® suppository applicator demonstrated sustained release with optimal bioavailability that is expected to provide consistent efficacy over the intended treatment period.

    New Data Highlights: Clinical Trial Methodology

    Title: Recent Recall as an Alternative to Daily Study Participant Diaries in Ulcerative Colitis Trials: Evidence from a Phase 3 Clinical Trial
    Key Findings: This prespecified exploratory analysis from the Phase 3 CESSA trial demonstrated that participant-reported UC symptom data collected through recent (3-day) recall correlated with data collected through daily participant diaries. These findings indicate that recent recall offers a reliable, lower-burden alternative to daily diaries for collecting patient-reported outcomes in future UC trials.

    Cristcot’s presence at ACG 2025 underscores its commitment to advancing evidence-based, patient-focused solutions that address persistent gaps in ulcerative colitis care.

    Additional information, including abstracts, can be found on the ACG 2025 Annual Meeting website.

    About Cristcot’s HCA 90 mg Suppository

    Cristcot’s investigational hydrocortisone acetate (HCA) 90 mg suppository formulation is a novel corticosteroid therapy delivering a small volume suppository using the Sephure® applicator to ensure precise placement, minimizing discomfort and leakage. Rectally administered topical treatments, including topical corticosteroids, are important treatment options (either alone or in combination with other therapies), for directing delivery to inflammation sites and limiting systemic drug exposure, though there is no FDA-approved corticosteroid suppository on the market. Unlike traditional corticosteroid treatments, Cristcot’s advanced HCA formulation allows for rapid, sustained release with optimal bioavailability, consistent and localized efficacy, and very limited systemic exposure. The innovative delivery system may enhance patient compliance.

    About Ulcerative Colitis

    UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms often include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients’ quality of life. UC flares frequently originate in the rectum, and untreated inflammation can progress to more extensive disease, leading to hospitalization or surgery. There is no cure for UC and, breakthrough flares, even while taking maintenance medication, is a known characteristic of the disease profile. Over 55% of UC patients experience 3-5 flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential. Gaps remain in addressing flares quickly and effectively, highlighting the need for targeted therapies that can provide rapid symptom relief and remission.

    About Cristcot

    Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company’s lead asset, a novel hydrocortisone acetate suppository, is positioned to become an important therapeutic option for ulcerative colitis. Cristcot’s diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Austin, Texas.

    For more information, please visit www.cristcot.com and connect with us on LinkedIn.

    Forward-Looking Statements

    Certain information set forth in this press release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Examples of forward-looking statements include, but are not limited to, statements regarding the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company’s products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company’s products; (vi) execution of the Company’s vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws.

    These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

    Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

    Contacts

    Jenny Gizzi, Chief Administrative Officer
    Cristcot
    [email protected]

    Tanner Kaufman / Katie Harris
    FTI Consulting
    [email protected] / [email protected]  

    SOURCE Cristcot

    Continue Reading

  • Nigeria’s Dangote plots refinery expansion part financed by stake sale

    Nigeria’s Dangote plots refinery expansion part financed by stake sale

    Stay informed with free updates

    Nigeria’s leading industrialist Aliko Dangote is planning to expand capacity at his group’s petroleum refinery to 1.4mn barrels per day and will sell shares in the business to help finance the expansion.

    Dangote told the Financial Times he would sell up to a 10 per cent stake in the refinery “depending on what the Nigerian market can take” and is also seeking $5bn in financing from Afreximbank, the African trade bank.

    The expansion, which the multi-billionaire industrialist announced in Lagos on Sunday, would make the refinery in Lagos, Nigeria’s commercial capital, rival Reliance Industries’ refinery at Jamnagar in India as the biggest in the world. Jamnagar says it has an output of 1.4mn barrels a day.

    The plant, which has an existing capacity of 650,000 barrels per day, has yet to reach full throttle.

    However, the plan reflected his confidence in the Nigerian economy and a response to rising regional demand, Dangote said, adding that it would help further reduce the continent’s dependence on imports.  

    “This expansion reflects our confidence in Nigeria’s future, our belief in Africa’s potential, and our commitment to building energy independence for our continent,” he said.

    Dangote is the only African on the Forbes list of the 100 wealthiest people in the world, with an estimated net worth of $26bn.

    Aliko Dangote is the only African on the Forbes list of the 100 wealthiest people © Victor J Blue/Bloomberg

    He said the expansion would require 65,000 workers, most of whom would be Nigerian, and expected it to take three years.

    The initial phase of the refinery took nearly a decade to construct from start to finish and cost about $20bn, and Dangote said he had learned lessons from the first phase to reduce the completion time of the second.

    George Elombi, the new president of Afreximbank, said his institution was in talks with the Dangote group to provide $5bn in loans towards the expansion.

    “We have agreed to look for the money so (the Dangote group) can double production, maximise certain production lines and thereby reduce the price of most of its products,” he told the Financial Times.

    This was part of a wider strategy the bank has begun in order to encourage industrialisation and increase support across the continent for the processing of raw materials, he said.  

    Since it began producing diesel and aviation fuel, and gasoline in 2024, the Dangote group has shaken up the Nigerian oil market, which after years of mismanagement at state-owned refineries had become dependent on costly imports of refined products.

    But it faced difficulties at the outset in securing enough oil from Nigeria’s national oil company NNPC, which owns a 7.2 per cent stake in the refinery.

    The group sourced crude from around the world with cargoes from Angola, Brazil, Equatorial Guinea, Ghana and the USA to satisfy demand, but has reduced inflows recently in response to rising global prices.

    At an Afreximbank event in Cairo on Saturday, Dangote said the refinery construction had been severely disrupted by the Covid-19 pandemic, but previous support from the African trade bank had helped see the project to completion.

    “Without Afreximbank the Dangote refinery wouldn’t have been possible,” he said.  

    Continue Reading

  • Biotechnology and Digital Health in Saudi Arabia and the UAE

    Biotechnology and Digital Health in Saudi Arabia and the UAE

    Introduction

    The Gulf Cooperation Council (GCC) is fast emerging as a global leader in biotechnology and digital health. This growth is driven by the unique mix of demographic pressures, economic diversification goals, and health security imperatives experienced in these countries. Saudi Arabia and the UAE are leading the sector’s regional expansion: Saudi Arabia’s recent launch of its National Biotechnology Strategy envisions a contribution of US$34.6 billion to non-oil GDP by 2040, while the UAE’s digital health market is forecast to grow by over 23 percent by 2030, pushing the sector to approximately US$2.65 billion in value.

    The expansion of such initiatives strengthens GCC countries’ reputations for delivering high-quality healthcare for both locals and expatriates and aligns with wider economic transformation agendas. The biotechnology industry and health tourism sector are lucrative opportunities with estimated values of US$1.5 trillion and US$8.7 billion, respectively.

    The biotechnology industry and health tourism sector are lucrative opportunities with estimated values of US$1.5 trillion and US$8.7 billion, respectively.

    However, while intensive public and private investment in initiatives such as digital health partnerships, national genome programmes, and AI-driven diagnostics mark major progress, the sector still faces bottlenecks in research infrastructure and data governance. Consolidating these advances through stronger coordination with research institutions and developing comprehensive health data governance frameworks will be key to turning early gains into lasting global leadership. 

    Diseases of modernity: rising wealth, sedentary lifestyles and ageing populations

    The Gulf states face a health paradox common to high-income societies: economic gains have brought prosperity and longevity, but also a surge in non-communicable diseases. The WHO estimates that around 74 million people in the Eastern Mediterranean live with diabetes, with prevalence rates in the GCC reaching up to 20 percent. At the same time, life expectancy has risen dramatically from 60 years in the late 1970s to around 83 years in 2025 in the UAE, with similar trends observed across the five other GCC states. This puts increasing pressure on both hospitals and home-based care services, given that 80 percent of healthcare needs typically occur post-retirement age.

    To meet these needs, states are seeking to implement new technologies within their healthcare offerings. Saudi Arabia’s Digital Health Strategy and Roadmap explicitly includes remote monitoring, virtual clinics, and the integration of telehealth as priorities under Vision 2030 and related health transformation programmes, incorporating technologies that can provide more accessible healthcare to citizens who may have limited mobility. This is also particularly important given Saudi Arabia’s large population and vast geography, as it enables care delivery to more people without extensive travel. In the UAE, ambitions for the health sector outlined in Vision 2021 and the more recent We the UAE 2031 consist of enhancing quality of life and specialised care offerings by continuing to develop an innovative, state-of-the-art healthcare system. As such, the Department of Health’s (DOH) Policy on Digital Health identifies technologies such as “telemedicine, web-based analysis…  wearable devices, and clinic or remote monitoring sensors” as essential for early diagnostics and care management.

    Next-generation sequencing and AI are being deployed to analyse population-wide genetic data, identifying variants linked to rare and hereditary disease.

    Alongside these efforts, the GCC is deepening its focus on gene mapping and preventative health. The Gulf’s high consanguinity rate among local populations has been a concern for decades, prompting Saudi Arabia to institute a law requiring pre-marital genetic testing in 2002 — the first such law in the region, subsequently adopted across all GCC states. Building on this foundation, targeted testing between couples has now been expanded as governments work to map entire populations. Next-generation sequencing and AI are being deployed to analyse population-wide genetic data, identifying variants linked to rare and hereditary disease. Such projects are essential to the development of “precision medicine”, in which the patient’s specific genetic profile is used to inform and optimise treatment plans rather than relying on generalised clinical guidelines. These programmes also address the Eurocentric bias in earlier datasets, creating population-specific genetic baselines that strengthen diagnostic accuracy.

    These initiatives position Gulf countries as leaders in data-driven healthcare, advancing Vision 2030 and We the UAE 2031 goals for economic diversification and improved quality of life. The UAE’s medical tourism market alone was valued at US$334.9 million in 2024, projected to reach US$975 million by 2032. By expanding biotechnology and digital health, both countries aim to extend life expectancy and ease pressure on healthcare systems as populations expand and age.

    Building momentum: investment, research and data regulation

    Biotechnology and digital health initiatives in the GCC are benefiting from significant levels of government commitment and capital investment. The healthcare-focused private equity company Quadria Capital recently allocated a quarter of its latest US$1 billion fund to the GCC, specifying digital health as a key sub-sector for growth and marking the region as a strategic hub for next-generation healthcare innovation. Saudi Arabia’s flagship Global Health Exhibition saw approximately US$13.3 billion in announced healthcare investment in 2024, and has dedicated a considerable tranche of activities and discussions to the topic of “Digital Health” for the upcoming 2025 edition in late October. In the UAE, the Abu Dhabi Department of Health and the Abu Dhabi Investment Office (ADIO) recently signed an MoU with GSK to establish a medical institute in the emirate, focused on integrating genomics data to advance cancer research. Another strength for the region is the positive reaction that genome projects have received from citizens. Because such projects necessitate a vast amount of data, the voluntary participation of citizens is an essential component. Public support is likely thanks in part to the existence of genetic testing as a pre-marital requirement, in addition to strong public messaging and education campaigns in both the UAE and Saudi Arabia that emphasise the transformative potential of AI’s algorithmic analyses and its central place in the GCC’s future economies.

    To ensure long-term competitiveness in medical tourism and biotechnology, GCC countries should expand research capacity alongside treatment infrastructure.

    However, challenges related to research capacity and infrastructure, which are uneven across the region, remain. While Abu Dhabi’s Masdar City and Dubai Science Park are key host centres for life sciences firms working in genomics and digital health, most clinical research remains concentrated in only a handful of facilities. The UAE, for example, has only eight on-site research centres across its 168 inpatient facilities. This is also true of Saudi Arabia, where specialist institutions like King Abdullah International Medical Research Center (KAIMRC), King Abdullah University of Science and Technology (KAUST), and King Abdulaziz City for Science and Technology (KACST) are impressive, but relatively few in number compared to global leaders in life sciences innovation, such as the US and Switzerland. To ensure long-term competitiveness in medical tourism and biotechnology, GCC countries should expand research capacity alongside treatment infrastructure. Developing research ecosystems would likely attract more global talent while simultaneously increasing economic gains by driving high-value innovation. In addition, future policy development in the evolving landscape of global data governance must balance security with flexibility — strong enough to guard against high-profile data breaches that have become a persistent risk across the sector, yet open enough to encourage biotech investment. Focusing on research depth and trusted data systems will position the GCC as a secure and innovation-driven healthcare hub.

    Conclusion

    Over the past decade, the GCC — led by Saudi Arabia and the UAE — has laid the groundwork for a modern, innovation-driven healthcare landscape. Through large-scale investment in the sector, including digital health initiatives and national genome programmes, the region is positioning itself as a global hub for precision medicine and data-driven health innovation. These initiatives address the challenges of population growth, increased life expectancy, and lifestyle-related diseases while supporting broader diversification goals under Vision 2030 and We the UAE 2031. Yet, progress remains uneven, particularly in research infrastructure and regulatory coherence — areas that will determine whether current momentum translates into lasting global influence.

    The strong investment trends in the wider sector should be matched by greater allocations toward building specialised research institutions to enable the region to generate original medical advances.

    Given that it is the UAE’s ambition to become a global destination for specialised care and Saudi Arabia’s mission to further encourage a competitive environment among healthcare providers, research capacity must become a priority. The strong investment trends in the wider sector should be matched by greater allocations toward building specialised research institutions to enable the region to generate original medical advances. In addition, GCC countries should seek to continuously advance and refine their health data regulations while avoiding overburdening market actors with excessive compliance duties, thereby balancing investor confidence with robust safeguards for privacy and ethical use.


    This commentary was originally appeared on ORF Middle East.

    The views expressed above belong to the author(s). ORF research and analyses now available on Telegram! Click here to access our curated content — blogs, longforms and interviews.

    Continue Reading